| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Global Blood Therapeutics Inc (NASDAQ: GBT)
GBT Technical Analysis
5
| As on 5th Oct 2022 GBT STOCK Price closed @ 68.49 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 31.77 & Strong Buy for SHORT-TERM with Stoploss of 38.22 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GBTSTOCK Price
| Open | 68.49 | Change | Price | % |
| High | 68.49 | 1 Day | 0.00 | 0.00 |
| Low | 68.49 | 1 Week | 0.50 | 0.74 |
| Close | 68.49 | 1 Month | 1.27 | 1.89 |
| Volume | N/A | 1 Year | 26.20 | 61.95 |
| 52 Week High 68.48 | 52 Week Low 22.30 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| HBIO | 0.63 | 40.00% |
| CMBM | 3.75 | 27.12% |
| NVDA | 202.89 | -2.00% |
| BYND | 1.65 | -10.33% |
| ONDS | 6.29 | -6.81% |
| LMDX | 0.02 | 0.00% |
| OPEN | 7.34 | -4.05% |
| AKTS | 0.04 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| GBT Daily Charts |
GBT Intraday Charts |
Whats New @ Bazaartrend |
GBT Free Analysis |
|
|
GBT Important Levels Intraday
| RESISTANCE | 68.49 |
| RESISTANCE | 68.49 |
| RESISTANCE | 68.49 |
| RESISTANCE | 68.49 |
| RESISTANCE | 68.49 |
| RESISTANCE | 68.49 |
| RESISTANCE | 68.49 |
| RESISTANCE | 68.49 |
GBT Forecast November 2025
| 4th UP Forecast | 87.43 |
| 3rd UP Forecast | 81.36 |
| 2nd UP Forecast | 77.6 |
| 1st UP Forecast | 73.85 |
| 1st DOWN Forecast | 63.13 |
| 2nd DOWN Forecast | 59.38 |
| 3rd DOWN Forecast | 55.62 |
| 4th DOWN Forecast | 49.55 |
GBT Weekly Forecast
| 4th UP Forecast | 79.22 |
| 3rd UP Forecast | 75.78 |
| 2nd UP Forecast | 73.65 |
| 1st UP Forecast | 71.53 |
| 1st DOWN Forecast | 65.45 |
| 2nd DOWN Forecast | 63.33 |
| 3rd DOWN Forecast | 61.20 |
| 4th DOWN Forecast | 57.76 |
GBT Forecast2025
| 4th UP Forecast | 167.48 |
| 3rd UP Forecast | 135.73 |
| 2nd UP Forecast | 116.11 |
| 1st UP Forecast | 96.49 |
| 1st DOWN Forecast | 40.49 |
| 2nd DOWN Forecast | 20.87 |
| 3rd DOWN Forecast | 1.25 |
| 4th DOWN Forecast | -30.5 |
Global Blood Therapeutics Inc ( NASDAQ USA Symbol : GBT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GBT Business Profile
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California. Address: 181 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service